Table 2.

Demographic data of patients receiving anti–PD-1 monotherapy

	Age, y	Gender	Malignancy	Therapy	TSH			Free T4			Free T3			TPO	TSI
					B	Thyrotoxicosis	Hypo	B	Thyrotoxicosis	Hypo	B	Thyrotoxicosis	Hypo
1	59	M	Anal cancer	Nivolumab	0.97	x	14.86	1.1	x	0.4	3.1	x	2	x	x
2	66	F	Breast ca.	Pembrolizumab	5.82	x	17.38	0.9	x	0.5	x	x	x	x	x
3	67	F	Breast ca.	Pembrolizumab	1.46	0.02	30.46	1.1	3.1	<0.4	x	x	x	x	x
4	62	F	Breast ca.	Pembrolizumab	2.62	0.13	16.7	1.3	1.7	0.6	x	x	x	x	x
5	62	F	Breast ca.	Pembrolizumab	0.4	0.03	20.46	1.7	2.4	0.5	x	x	x	x	x
6	44	F	Breast ca.	Pembrolizumab	2.63	0.04	56.41	1	1.8	0.3	3.5	x	x	x	x
7	42	F	GBM of brain	Nivolumab	1.55	0.09	31.62	1.1	2.3	<0.3	2.8	4.7	<1.4	x	x
8	55	F	Leiomyosarcoma	Pembrolizumab	5.54	x	54.79	1.2	x	0.6	x	x	<1.4	73.6	x
9	50	F	Leiomyosarcoma	Pembrolizumab	2.57	x	58.93	1	x	0.4	x	x	x	x	x
10	49	M	Melanoma	Pembrolizumab	2.56	x	187.82	x	x	x	x	x	x	20.7	x
11	77	F	Melanoma	Nivolumab	1.64	x	79.66	1	x	0.4	x	x	x	250.7	x
12	54	M	Melanoma	Pembrolizumab	1.15	0.01	x	1.4	2.5	x	x	x	x	x	<1
13	55	F	Melanoma	Pembrolizumab	1.14	0.21	9.22	0.8	x	1.1	x	x	x	x	<1
14	73	F	Melanoma	Pembrolizumab	1.09	0.01	32.64	x	x	0.4	x	x	x	149	x
15	72	M	Melanoma	Pembrolizumab	2.06	0.03	67.44	1	1.8	<0.3	2.2	x	x	93.8	<1
16	55	F	Melanoma	Pembrolizumab	2.66	x	56.78	x	x	<0.3	x	x	x	x	x
17	41	F	Melanoma	Pembrolizumab	0.49	0.03	x	x	2.7	x	x	5.9	x	x	x
18	55	F	Melanoma	Nivolumab	1.37	x	21.82	x	x	x	x	x	x	x	x

Abbreviations: M, male; F, female; B, baseline; hypo, hypothyroidism; GBM, glioblastoma; TSH, thyroid stimulating hormone; free T4, free thyroxine; free T3, free triiodothyronine.